Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: New concepts for cardiovascular disease

Cardiovascular Research

Volumn 49, Issue 2, 2001, Pages 281-287

  Lefer, Allan M ^a   Scalia, Rosario ^a   Lefer, David J ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Cholesterol; Lipid metabolism

Indexed keywords

CHOLESTEROL; COMPACTIN; ISOPRENOID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; NITROUS OXIDE; STATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; ENZYME INHIBITION; FOLLOW UP; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; CORONARY VESSELS; ENDOTHELIN-1; ENDOTHELINS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; FREE RADICAL SCAVENGERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MUSCLE, SMOOTH, VASCULAR; NEUTROPHIL INFILTRATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN PRECURSORS; SIMVASTATIN;

EID: 0035254465     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00247-9     Document Type: Review

References (53)

1. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum
2. Discovery biochemistry and biology of lovastatin
3. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
4. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study
5. Role of endothelial dysfunction in the pathogenesis of reperfusion injury following myocardial ischemia
6. Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment
7. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock
8. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute
9. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms
10. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
11. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
12. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points
13. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
14. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
15. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase cerebral bloodflow/cerebral ischemia
16. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
17. Nitric oxide in myocardial and splanchnic ischemia/reperfusion
18. Therapeutic role of nitric oxide donors in the treatment of cardiovascular disease
19. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
20. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
21. A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: Possible relevance of up-regulation of endothelial NO synthase mRNA
22. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment
23. Direct measurement of nitric oxide release from vascular endothelial cells
24. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
25. Simvastatin inhibits leukocyte-endothelium interaction in vivo under normocholesterolemic conditions: Essential role of endothelial nitric oxide synthase
26. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats
27. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats
28. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide
29. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line
30. Low-density lipoprotein-independent effects of statins
31. Effect of simvastatin therapy on cell membrane cholesterol content and membrane function as assessed by polymorphonuclear cell NADPH oxidase activity
32. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes
33. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, an HMG-CoA reductase inhibitor
34. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
35. HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
36. Inhibition of tissue-factor-mediated thrombin generation by simvastatin
37. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin
38. Direct vascular effects of HMG-CoA reductase inhibitors
39. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
40. Mechanisms of vascular preservation by a novel NO donor following rat carotid artery intimal injury
41. HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density
42. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
43. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease
44. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels
45. Type II diabetes abrogates sex differences in endothelial function in premenopausal women
46. Simvastatin attenuates leukocyte-endothelium interaction in Type-II diabetic mice
47. Effect of lovastatin on cerebral circulation in spontaneously hypertensive rats
48. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial
49. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury
50. Non-lipid-related effects of statins
51. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction
52. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans